Skip to main content
SpringerLink
Log in

Coagulation Disorders and Management

  • Chapter
  • First Online:
COVID-19 Critical and Intensive Care Medicine Essentials

  • 445 Accesses

Abstract

Coronavirus Disease-19 (COVID-19), caused by SARS-CoV-2 infection, is associated with a rise in inflammatory markers which can result in altered coagulation system activation and regulation. During COVID-19, a remarkable tendency towards venous thrombosis and thrombo-embolism has been widely reported, especially in the critically ill patients. Thus, to limit this clinically relevant events, various strategies of venous thrombo-prophylaxis and anticoagulation have been studied. On the other hand, arterial thrombosis seems to play a less relevant role the clinical picture of COVID-19, as much as bleeding complications, which are mostly correlated to anticoagulation management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

    Article  CAS  PubMed  Google Scholar 

  2. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500.

    Article  CAS  PubMed  Google Scholar 

  3. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):4–11.

    Article  Google Scholar 

  4. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Suh Y, Hong H, Ohana M, Bompard F, Revel M-P, Valle C, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2020;298:E70–80.

    Article  PubMed  Google Scholar 

  6. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.

    Article  CAS  PubMed  Google Scholar 

  8. Levi M, Hunt BJ. Thrombosis and coagulopathy in COVID-19: an illustrated review. Res Pract Thromb Haemost. 2020;4(5):744–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Xiang G, Hao S, Fu C, Hu W, Xie L, Wu Q, et al. The effect of coagulation factors in 2019 novel coronavirus patients: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(7):e24537.

    Article  CAS  Google Scholar 

  10. Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020;383(3):288–90.

    Article  PubMed  Google Scholar 

  11. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–42.

    Article  CAS  PubMed  Google Scholar 

  12. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–51.

    Article  CAS  PubMed  Google Scholar 

  13. Gomez-Builes JC, Acuna SA, Nascimento B, Madotto F, Rizoli SB. Harmful or physiologic: diagnosing fibrinolysis shutdown in a trauma cohort with rotational thromboelastometry. Anesth Analg. 2018;127(4):840–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Creel-Bulos C, Auld SC, Caridi-Scheible M, Barker NA, Friend S, Gaddh M, et al. Fibrinolysis shutdown and thrombosis in a COVID-19 ICU. Shock. 2021;55(3):316–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bachler M, Bösch J, Stürzel DP, Hell T, Giebl A, Ströhle M, et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth. 2020;126(3):590–8.

    Article  PubMed  CAS  Google Scholar 

  16. Thachil J. Usefulness of combining d-dimers with thromboelastography. J Am Coll Surg. 2020;231(5):608.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wright F, Vogler T, Moore E, Moore H, Wohlauer M, Urban S, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;231(2):193–203.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;1(191):148–50.

    Article  CAS  Google Scholar 

  19. Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest. 2021;159(3):1182–96.

    Article  PubMed  CAS  Google Scholar 

  20. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324(8):799–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Prophylaxis in Medical Patients with Enoxaparin Study Group, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793–800.

    Article  CAS  PubMed  Google Scholar 

  22. Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874–9.

    Article  CAS  PubMed  Google Scholar 

  23. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med. 2004;10(5):356–65.

    Article  CAS  PubMed  Google Scholar 

  25. Harr JN, Moore EE, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock. 2013;39:45–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol. 2020;319(2):L211–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gozzo L, Viale P, Longo L, Vitale DC, Drago F. The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review. Front Pharmacol. 2020;11:1307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. de Montmollin E, Faille D, Andrieu V, Ajzenberg N, Timsit J-F. Intensified thromboprophylaxis in COVID-19 critically ill patients: is it enough? J Infect. 2021;82(5):e20–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9. https://doi.org/10.1111/jth.14817.

    Article  CAS  PubMed  Google Scholar 

  30. Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Martinelli I, Ciavarella A, Abbattista M, Aliberti S, De Zan V, Folli C, et al. Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern Emerg Med. 2021;16(5):1223–9.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Tacquard C, Mansour A, Godon A, Godet J, Poissy J, Garrigue D, et al. Impact of high dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia. Chest. 2021;159(6):2417–27.

    Article  CAS  PubMed  Google Scholar 

  33. Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(16):1815–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305–14.

    Article  Google Scholar 

  35. Halaby R, Cuker A, Yui J, Matthews A, Ishaaya E, Traxler E, et al. Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: a retrospective cohort study. J Thromb Haemost JTH. 2021;19(6):1533–45.

    Article  CAS  PubMed  Google Scholar 

  36. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6. https://doi.org/10.1111/jth.14810.

    Article  CAS  PubMed  Google Scholar 

  37. Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50(1):72–81. https://doi.org/10.1007/s11239-020-02138-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143–63.

    Article  CAS  PubMed  Google Scholar 

  39. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167. https://doi.org/10.2450/2020.0083-20.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Al-Samkari H, Gupta S, Leaf RK, Wang W, Rosovsky RP, Brenner SK, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann Intern Med. 2021;26:M20–6739.

    Google Scholar 

  41. INSPIRATION Investigators, Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–30.

    Article  CAS  Google Scholar 

  42. The REMAP-CAP, ACTIV-4a, ATTACC Investigators, Zarychanski R. Therapeutic anticoagulation in critically ill patients with Covid-19—preliminary report. Intensive Care Crit Care Med. 2021. Accessed 29 Mar 2021. https://doi.org/10.1101/2021.03.10.21252749

  43. Yuriditsky E, Horowitz JM, Merchan C, Ahuja T, Brosnahan SB, McVoy L, et al. Thromboelastography profiles of critically ill patients with coronavirus disease 2019. Crit Care Med. 2020;48(9):1319–26.

    Article  CAS  PubMed  Google Scholar 

  44. Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020;18(9):2215–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752–5. https://doi.org/10.1111/jth.14828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77(15):1903–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. O’Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Med. 2021;47(8):899–902.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Goshua G, Pine AB, Meizlish ML, Chang C-H, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–82.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Uba T, Nishi K, Umegaki T, Ohashi N, Kusaka Y, Umegaki O, et al. The influence of human soluble recombinant thrombomodulin on in-hospital mortality in patients with acute respiratory distress syndrome and disseminated intravascular coagulation: a retrospective multicenter study. J Intensive Crit Care. 2017;3(3):40. http://criticalcare.imedpub.com/the-influence-of-human-soluble-recombinant-thrombomodulin-on-inhospital-mortality-in-patients-with-acute-respiratory-distress-synd.php?aid=21017.

    Google Scholar 

  50. Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration. 2017;93(3):212–25.

    Article  CAS  PubMed  Google Scholar 

  51. Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64.

    Article  CAS  PubMed  Google Scholar 

  52. Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol. 2008;294(5):L874–81.

    Article  CAS  PubMed  Google Scholar 

  53. Camprubí-Rimblas M, Tantinyà N, Bringué J, Guillamat-Prats R, Artigas A. Anticoagulant therapy in acute respiratory distress syndrome. Ann Transl Med. 2018;6(2):36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Koyama K, Katayama S, Tonai K, Shima J, Koinuma T, Nunomiya S. Biomarker profiles of coagulopathy and alveolar epithelial injury in acute respiratory distress syndrome with idiopathic/immune-related disease or common direct risk factors. Crit Care. 2019;23(1):283.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Rehberg S, Yamamoto Y, Sousse LE, Jonkam C, Zhu Y, Traber LD, et al. Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury. Crit Care Med. 2013;41(12):e439–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Rehberg S, Yamamoto Y, Sousse LE, Jonkam C, Cox RA, Prough DS, et al. Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome. J Trauma Acute Care Surg. 2014;76(1):126–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Lowenstein CJ, Solomon SD. Severe COVID-19 is a microvascular disease. Circulation. 2020;142(17):1609–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesia and Intensive Care, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Mauro Panigada

  2. Department of Anesthesiology, Intensive Care and Emergency, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Andrea Meli

  3. Department of Pediatrics INOVA Heart and Vascular Institute Falls Church, Virginia, VA, USA

    Heidi J. Dalton

Authors
  1. Mauro Panigada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Meli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heidi J. Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Anesthesia and Critical Care Unit, Ospedale San Martino, Genova, Italy

    Denise Battaglini

  2. Anesthesia and Critical Care, Ospedale San Martino, Genoa, Italy

    Paolo Pelosi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Panigada, M., Meli, A., Dalton, H.J. (2022). Coagulation Disorders and Management. In: Battaglini, D., Pelosi, P. (eds) COVID-19 Critical and Intensive Care Medicine Essentials. Springer, Cham. https://doi.org/10.1007/978-3-030-94992-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94992-1_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94991-4

  • Online ISBN: 978-3-030-94992-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation